Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

• Status: Terminated
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag, S.A.
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Patients with Schizophrenia or Schizoaffective disorder, in which physicians considered the use of risperidone as treatment under clinical practice with a BMI >25

• Patients have increased their body weight >7% in the last year with the previous treatment even with a BMI< 25

• Patients that have shown intolerance to a previous antipsychotic treatment

Exclusion Criteria:

• Pregnant or lactating patients

• Patients with psychiatry pathology other than Schizophrenia or schizoaffective disorder

• Patients with neurology pathology except Parkinsonism induced by neuroleptics

• Patients with other severe concomitant pathology

• Patients treated with Risperidone in the last 30 days.